Efficacy response | Number of patients (N = 36) |
---|---|
Complete response | 0 (0%) |
Partial response | 2 (5.6%) |
Stable disease | 14 (38.9%) |
Progressive disease | 20 (55.6%) |
4-Month clinical benefit rate (4-CBR) | 10 (27.8%) |
6-Month clinical benefit rate (6-CBR) | 6 (16.7%) |